Novel medications targeting cellular motor proteins
Total Trials
1
As Lead Sponsor
As Collaborator
0
Total Enrollment
36
NCT07185880
A Phase 1 Study of the Safety and Tolerability of MT-125 in GBM Patients
Phase: Phase 1
Role: Lead Sponsor
Start: Nov 1, 2025
Completion: Jun 30, 2027
Loading map...